{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:01:24Z","timestamp":1769691684942,"version":"3.49.0"},"reference-count":47,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-018-0470-3","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T15:51:46Z","timestamp":1546962706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Kerstin","family":"Kapp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Volz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burghardt","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-2789","authenticated-orcid":false,"given":"Manuel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"4","key":"470_CR1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.coph.2012.06.002","volume":"12","author":"DJ Connolly","year":"2012","unstructured":"Connolly DJ, O'Neill LA. New developments in toll-like receptor targeted therapeutics. Curr Opin Pharmacol. 2012;12(4):510\u20138.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"470_CR2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/onci.20696","volume":"1","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(5):699\u2013716.","journal-title":"Oncoimmunology."},{"issue":"5","key":"470_CR3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","volume":"13","author":"H Kanzler","year":"2007","unstructured":"Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med. 2007;13(5):552\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"470_CR4","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","volume":"168","author":"V Hornung","year":"2002","unstructured":"Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531\u20137.","journal-title":"J Immunol"},{"issue":"10","key":"470_CR5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987\u201395.","journal-title":"Nat Immunol"},{"issue":"4","key":"470_CR6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","volume":"4","author":"DM Klinman","year":"2004","unstructured":"Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"470_CR7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","volume":"117","author":"AM Krieg","year":"2007","unstructured":"Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184\u201394.","journal-title":"J Clin Invest"},{"issue":"5","key":"470_CR8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/17460440902824784","volume":"4","author":"AA Tarhini","year":"2009","unstructured":"Tarhini AA, Kirkwood JM, Krieg AM. Early development of the toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov. 2009;4(5):587\u2013603.","journal-title":"Expert Opin Drug Discov"},{"issue":"8","key":"470_CR9","doi-asserted-by":"crossref","first-page":"e25238","DOI":"10.4161\/onci.25238","volume":"2","author":"E Vacchelli","year":"2013","unstructured":"Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013;2(8):e25238.","journal-title":"Oncoimmunology"},{"issue":"5124","key":"470_CR10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.8351515","volume":"261","author":"CA Stein","year":"1993","unstructured":"Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993;261(5124):1004\u201312.","journal-title":"Science"},{"issue":"5","key":"470_CR11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V92.5.1617","volume":"92","author":"JP Sheehan","year":"1998","unstructured":"Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood. 1998;92(5):1617\u201325.","journal-title":"Blood"},{"issue":"8","key":"470_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0006-2952(97)00091-9","volume":"53","author":"DR Shaw","year":"1997","unstructured":"Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang Z, Agrawal S. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol. 1997;53(8):1123\u201332.","journal-title":"Biochem Pharmacol"},{"issue":"43","key":"470_CR13","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","volume":"269","author":"DA Brown","year":"1994","unstructured":"Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, Sullivan S, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994;269(43):26801\u20135.","journal-title":"J Biol Chem"},{"issue":"2","key":"470_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.20140391","volume":"212","author":"U Flierl","year":"2015","unstructured":"Flierl U, Nero TL, Lim B, Arthur JF, Yao Y, Jung SM, et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med. 2015;212(2):129\u201337.","journal-title":"J Exp Med"},{"issue":"12","key":"470_CR15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","volume":"2","author":"SP Henry","year":"2002","unstructured":"Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002;2(12):1657\u201366.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"470_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","volume":"1489","author":"AA Levin","year":"1999","unstructured":"Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta. 1999;1489(1):69\u201384.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"470_CR17","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264\u201377.","journal-title":"J Clin Invest"},{"issue":"2","key":"470_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nm987","volume":"10","author":"M Heikenwalder","year":"2004","unstructured":"Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187\u201392.","journal-title":"Nat Med"},{"issue":"3","key":"470_CR19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2015.0533","volume":"25","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Hagner N, Marco A, Konig-Merediz SA, Schroff M, Design WB. Structural requirements of the potent and safe TLR-9 agonistic Immunomodulator MGN1703. Nucleic Acid Ther. 2015;25(3):130\u201340.","journal-title":"Nucleic Acid Ther"},{"issue":"19","key":"470_CR20","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","volume":"29","author":"V Hirsh","year":"2011","unstructured":"Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(19):2667\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"470_CR21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/annonc\/mdr030","volume":"23","author":"C Manegold","year":"2012","unstructured":"Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012;23(1):72\u20137.","journal-title":"Ann Oncol"},{"key":"470_CR22","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/mtna.2014.28","volume":"3","author":"K Kapp","year":"2014","unstructured":"Kapp K, Kleuss C, Schroff M, Wittig B. Genuine immunomodulation with dSLIM. Mol Ther Nucleic Acids. 2014;3:e170.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"470_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drudis.2014.09.004","volume":"20","author":"A Vater","year":"2015","unstructured":"Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer((R)) therapeutics. Drug Discov Today. 2015;20(1):147\u201355.","journal-title":"Drug Discov Today"},{"issue":"25","key":"470_CR24","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1021\/ja00051a001","volume":"114","author":"GW Ashley","year":"1992","unstructured":"Ashley GW. Modeling, Synthesis, and hybridization properties of (L)-ribonucleic acid. J Am Chem Soc. 1992;114(25):9731\u20136.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"470_CR25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nbt0996-1112","volume":"14","author":"S Klussmann","year":"1996","unstructured":"Klussmann S, Nolte A, Bald R, Erdmann VA, Furste JP. Mirror-image RNA that binds D-adenosine. Nat Biotechnol. 1996;14(9):1112\u20135.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"470_CR26","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.4049\/jimmunol.170.7.3614","volume":"170","author":"KJ Stacey","year":"2003","unstructured":"Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, et al. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol. 2003;170(7):3614\u201320.","journal-title":"J Immunol"},{"issue":"6","key":"470_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","volume":"27","author":"AM Krieg","year":"2004","unstructured":"Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004;27(6):460\u201371.","journal-title":"J Immunother"},{"issue":"12","key":"470_CR28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","volume":"5","author":"M Colonna","year":"2004","unstructured":"Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219\u201326.","journal-title":"Nat Immunol"},{"issue":"10","key":"470_CR29","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208(10):2005\u201316.","journal-title":"J Exp Med"},{"issue":"10","key":"470_CR30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989\u20132003.","journal-title":"J Exp Med"},{"issue":"1","key":"470_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.68.1.1","volume":"68","author":"JA Belperio","year":"2000","unstructured":"Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68(1):1\u20138.","journal-title":"J Leukoc Biol"},{"issue":"9","key":"470_CR32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol."},{"key":"470_CR33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","volume":"15","author":"U Boehm","year":"1997","unstructured":"Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"470_CR34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/iid3.126","volume":"4","author":"K Kapp","year":"2016","unstructured":"Kapp K, Schneider J, Schneider L, Gollinge N, Jansch S, Schroff M, et al. Distinct immunological activation profiles of dSLIM\u00ae and ProMune\u00ae depend on their different structural context. Immun Inflamm Dis. 2016;4(4):446\u201362.","journal-title":"Immun Inflamm Dis"},{"issue":"8","key":"470_CR35","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.4049\/jimmunol.170.8.4061","volume":"170","author":"SE Blackwell","year":"2003","unstructured":"Blackwell SE, Krieg AM. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol. 2003;170(8):4061\u20138.","journal-title":"J Immunol"},{"issue":"11","key":"470_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","volume":"3","author":"LL Woude van der","year":"2017","unstructured":"van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM. Migrating into the tumor: a roadmap for T cells. Trends Cancer. 2017;3(11):797\u2013808.","journal-title":"Trends Cancer"},{"key":"470_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","volume":"1036","author":"TF Gajewski","year":"2017","unstructured":"Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19\u201331.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"470_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","volume":"28","author":"S Spranger","year":"2016","unstructured":"Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28(8):383\u201391.","journal-title":"Int Immunol"},{"issue":"6","key":"470_CR39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","volume":"164","author":"AK Palucka","year":"2016","unstructured":"Palucka AK, Coussens LM. The basis of Oncoimmunology. Cell. 2016;164(6):1233\u201347.","journal-title":"Cell"},{"issue":"7693","key":"470_CR40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"1","key":"470_CR41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","volume":"5","author":"SI Mosely","year":"2017","unstructured":"Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res. 2017;5(1):29\u201341.","journal-title":"Cancer Immunol Res"},{"key":"470_CR42","doi-asserted-by":"crossref","unstructured":"Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18).","DOI":"10.1172\/jci.insight.93397"},{"issue":"46","key":"470_CR43","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","volume":"113","author":"S Wang","year":"2016","unstructured":"Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113(46):E7240\u2013E9.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"470_CR44","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, et al. SD-101 in combination with Pembrolizumab in advanced melanoma: results of a phase Ib. Multicenter Study Cancer Discov. 2018;8(10):1250\u20137.","journal-title":"Multicenter Study Cancer Discov"},{"issue":"1","key":"470_CR45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2014.12.002","volume":"94","author":"B Wittig","year":"2015","unstructured":"Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol. 2015;94(1):31\u201344.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"470_CR46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","volume":"19","author":"T Kawai","year":"2007","unstructured":"Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19(1):24\u201332.","journal-title":"Semin Immunol"},{"issue":"1","key":"470_CR47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2008.02050.x","volume":"265","author":"C Guiducci","year":"2009","unstructured":"Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med. 2009;265(1):43\u201357.","journal-title":"J Intern Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:03:49Z","timestamp":1694545429000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0470-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"article-number":"5"}}